Prosecution Insights
Last updated: November 05, 2026
Application No. 18/273,458

MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME

Final Rejection §102§112§DOUBLEPATENT
Filed
Jul 20, 2023
Priority
Feb 08, 2021 — provisional 63/146,785 +3 more
Examiner
SAWYER, JENNIFER C
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rappta Therapeutics OY
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
60%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
388 granted / 566 resolved
+8.6% vs TC avg
Minimal -8% lift
Without
With
+-8.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
53 currently pending
Career history
623
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
48.8%
+8.8% vs TC avg
§102
13.6%
-26.4% vs TC avg
§112
26.7%
-13.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 566 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This office action is in response to applicant’s communication filed on 8/21/26. Claims 1, 3, 15-28 and 30-34 are pending in this application. Claims 3, 15-16, 19-20, 23-25, 28, 30, 32-34 remain withdrawn. Due to applicant’s claim amendments filed 8/21/26, the claim objection and the 103 rejection over Jozefiak et al. are withdrawn. However, based on a new search in response to applicant’s amended claims, new rejections are in order. Applicant’s elected species is the following compound: PNG media_image1.png 278 386 media_image1.png Greyscale Applicant’s elected species remains allowable. Thus the new species to be examined is the following: PNG media_image2.png 380 572 media_image2.png Greyscale N-tosyl-L-phenylalanine, i.e., (S)-2-((4-methylphenyl)sulfonamido)-3-phenylpropanoic acid Claims 1, 15-17 and 31 read on the new species. Thus, additionally, claims 18, 21-22 and 26-27 are hereby withdrawn from consideration being non-readable on the new species. The search has not been extended to determine the patentability of the other species encompassed by the claims. As a result, claims 1, 15-17 and 31 are being examined in this Office Action. Claims 1, 3, 15-28 and 30-34 are pending in this application. Claims 3, 18-28, 30 and 32-34 are withdrawn. With regard to applicant’s request for rejoinder of claims withdrawn for being non-readable on the new species, since the new species reads on claims 1, 15-17 and 31, claims 3, 18-28 and 30 that do not read on the new species can be withdrawn since the search is not extended to determine the patentability of the other species encompassed by the claims. Claim Rejections – 35 USC 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1, 15-17 and 31 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 1 recites proviso (c): “the phenyl in Z is substituted with at least one trifluoromethoxy substituent, the C6-C10 aryl in R2 is substituted with at least one substituent, and R3 is optionally substituted C1-C6 aminoalkyl”. However, amended claim 1 defines R3 as H or C1-C3 alkyl. Also, R3 is only found in the second R1 group, which has no R2. Thus proviso (c) can never be met. It is not clear if R3 can be an aminoalkyl. It is also not clear which compounds proviso (c) is meant to cover. Claims 15-17 and 31 are rejected as being dependent on claim 1. Claim Rejections – 35 USC 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 15-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pyne et al. (“Cytochalasin Support Studies. 2. Chiral and Stereochemical Control via an Intramolecular Diels-Alder Reaction of a (Z)-Diene,” J. Am. Chem. Soc., 1980, 102(18), pages 5960-5962, pub date 1980). The instant claims are drawn to the following compound of formula (I): PNG media_image3.png 143 289 media_image3.png Greyscale where R1 can be the following group: PNG media_image4.png 270 255 media_image4.png Greyscale Pyne et al. teaches the N-tosyl derivative of L-phenylalanine, compound 7. Pyne et al. defines Ts as p-CH3-C6H4SO2 (see compound below). (page 5960, second column, last paragraph; page 5961, Scheme I, compound 7): PNG media_image5.png 187 194 media_image5.png Greyscale PNG media_image2.png 380 572 media_image2.png Greyscale Pyne et al. compound 7 reads on applicant’s compound of formula (I): Z = 4-methyl substituted phenyl L = bond A1 = PNG media_image6.png 187 184 media_image6.png Greyscale R1 = PNG media_image7.png 130 90 media_image7.png Greyscale where R4 = Ra1 = Ra2 = H, T2 = phenyl and Y2 = OH (ORa, Ra = H) R1 has no R2. Thus the proviso of claim 1 does not apply. With regard to claims 15-17, compound 7 is a compound of formula (II) (see compound (II) below), Ar-S(O)2-NH-R1, where Ar is 4-methylphenyl. Claim 16 recites Ar as phenyl with X1 at the 4-position, where X1 is methyl. Claim 17 recites Ar as 4-methylphenyl. PNG media_image8.png 70 122 media_image8.png Greyscale Therefore these claims are fully met. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Claims 1, 15-17 and 31 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 45, 81 and 82 of copending Application No. 18993421 (the PGPub is used herein: US 20260265190). Although the claims at issue are not identical, they are not patentably distinct from each other because of the following: Copending application’s claim 81 recites the following compounds: 1) N-(1-(3,4-difluorophenyl)-2-(piperazin-1-yl)ethyl)-4-(trifluoromethoxy)benzenesulfonamide (page 18); and 2) N-(1-(3,4-dichlorophenyl)-2-(dimethylamino)ethyl)-4-(3-(trifluoromethyl)phenoxy)benzenesulfonamide (page 20; claim 45, page 17). Compound 1) reads on instant claims 1, 15-17, 23 and 26, when: Z = Ar = 4-trifluoromethoxy substituted phenyl; L = bond; A1 = -S(=O)2-NH-R1 R1 = the first R1 group, where R2 = 3,4-difluorophenyl, R4 = Ra1 = Ra2 = H, and RA and RB combine to form a piperazine (A2 = 3,4-difluorophenyl and A3 = piperazin-1-yl of claim 23) Proviso (a) of claim 1 is met. The phenyl in Z has a trifluoromethoxy and R2 has a fluoro. Compound 2) reads on the instant claims, when: Z = Ar = 4-(3-(trifluoromethyl)phenoxy) substituted phenyl; L = bond; A1 = -S(=O)2-NH-R1 R1 = the first R1 group, where R2 = 3,4-dichlorophenyl, R4 = Ra1 = Ra2 = H, and RA = RB = methyl Proviso (a) of claim 1 is met. The phenyl in Z has a C6-C10 aryloxy and R2 has a chloro. Thus copending application’s claims 45 and 81 anticipate instant claims 1, 15-17 and 31 Copending application’s claim 82 recites a pharmaceutical composition of the compounds of claim 1 and a pharmaceutically acceptable carrier. Thus it would be obvious to also combine compound 1) or 2) above with a pharmaceutically acceptable carrier, to use them as PP2A modulators. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Cho Sawyer whose telephone number is (571) 270 1690. The examiner can normally be reached on Monday-Friday 9 AM - 6 PM PST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-274-1690. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JENNIFER C SAWYER/Examiner, Art Unit 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Jul 20, 2023
Application Filed
Jun 04, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT
Aug 21, 2026
Response Filed
Oct 20, 2026
Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780775
IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES
3y 5m to grant Granted Nov 03, 2026
Patent 12759975
METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY
4y 0m to grant Granted Oct 13, 2026
Patent 12759970
POLYHYDROXY MULTI-IONIC COMPOUNDS AND METHODS OF MAKING AND USE THEREOF
3y 5m to grant Granted Oct 13, 2026
Patent 12752286
Mining Collectors
4y 3m to grant Granted Oct 06, 2026
Patent 12747201
IODINATED COMPOUNDS HAVING RADIOCONTRAST PROPERTIES
2y 4m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
60%
With Interview (-8.1%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 566 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month